Literature DB >> 24925639

LC-MS/MS analysis of plasma polyunsaturated fatty acids in patients with homozygous sickle cell disease.

Mutay Aslan1, Gamze Celmeli, Filiz Özcan, Alphan Kupesiz.   

Abstract

The aim of this study was to determine circulating omega-6, omega-3 polyunsaturated fatty acids and prostaglandin E2 (PGE2) levels in steady state sickle cell disease (SCD) patients. Blood was collected from healthy hemoglobin volunteers and steady state homozygous HbSS patients who had not received blood transfusions in the last 3 months. Plasma levels of arachidonic acid (AA, C20:4n-6), dihomo-gamma-linolenic acid (DGLA, C20:3n-6), eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) were determined by an optimized multiple reaction monitoring method using ultrafast liquid chromatography coupled with tandem mass spectrometry. PGE2 was measured in serum samples by enzyme immunoassay. Plasma AA and DGLA were significantly increased while EPA and DHA were significantly decreased in SCD plasma compared to control. Serum PGE2 levels, AA/DHA and AA/EPA ratio was significantly higher in SCD patients when compared to control group. The significant increase in PGE2 levels, AA/EPA and AA/DHA ratio confirms the presence of a proinflammatory state in SCD patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24925639     DOI: 10.1007/s10238-014-0293-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  31 in total

1.  Diagnosis of hemoglobinopathies: electrophoresis vs. HPLC.

Authors:  C N Ou; C L Rognerud
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

2.  Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells.

Authors:  M D Brown; T M Wick; J R Eckman
Journal:  Pediatr Pathol Mol Med       Date:  2001 Jan-Feb

3.  Chromatographic measurements of hemoglobin A2 in blood samples that contain sickle hemoglobin.

Authors:  M Shokrani; F Terrell; E A Turner; M D Aguinaga
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

Review 4.  Fatty acid modulation of endothelial activation.

Authors:  R De Caterina; J K Liao; P Libby
Journal:  Am J Clin Nutr       Date:  2000-01       Impact factor: 7.045

Review 5.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Abnormal phospholipid molecular species of erythrocytes in sickle cell anemia.

Authors:  W E Connor; D S Lin; G Thomas; F Ey; T DeLoughery; N Zhu
Journal:  J Lipid Res       Date:  1997-12       Impact factor: 5.922

7.  Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease.

Authors:  T R Kinney; L A Sleeper; W C Wang; R A Zimmerman; C H Pegelow; K Ohene-Frempong; D L Wethers; J A Bello; E P Vichinsky; F G Moser; D M Gallagher; M R DeBaun; O S Platt; S T Miller
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

8.  Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids.

Authors:  B N Setty; D Chen; M J Stuart
Journal:  Pediatr Res       Date:  1995-07       Impact factor: 3.756

9.  Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells.

Authors:  E J Bates; A Ferrante; L Smithers; A Poulos; B S Robinson
Journal:  Atherosclerosis       Date:  1995-08       Impact factor: 5.162

10.  Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.

Authors:  E Graido-Gonzalez; J C Doherty; E W Bergreen; G Organ; M Telfer; M A McMillen
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more
  6 in total

1.  Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).

Authors:  Ahmed A Daak; Carlton D Dampier; Beng Fuh; Julie Kanter; Ofelia A Alvarez; L Vandy Black; Melissa A McNaull; Michael U Callaghan; Alex George; Lynne Neumayr; Lee M Hilliard; Fredrick Sancilio; Adrian L Rabinowicz; Matthew M Heeney
Journal:  Blood Adv       Date:  2018-08-14

2.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694

3.  Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease.

Authors:  Hongyu Wu; Mikhail Bogdanov; Yujin Zhang; Kaiqi Sun; Shushan Zhao; Anren Song; Renna Luo; Nicholas F Parchim; Hong Liu; Aji Huang; Morayo G Adebiyi; Jianping Jin; Danny C Alexander; Michael V Milburn; Modupe Idowu; Harinder S Juneja; Rodney E Kellems; William Dowhan; Yang Xia
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

4.  Maternal Aerobic Exercise, but Not Blood Docosahexaenoic Acid and Eicosapentaenoic Acid Concentrations, during Pregnancy Influence Infant Body Composition.

Authors:  Cody J Strom; Samantha M McDonald; Mary-Margaret Remchak; Kimberly A Kew; Blake R Rushing; Joseph A Houmard; David A Tulis; Roman Pawlak; George A Kelley; Lisa Chasan-Taber; Edward Newton; Christy Isler; James DeVente; Madigan Raper; Linda E May
Journal:  Int J Environ Res Public Health       Date:  2022-07-07       Impact factor: 4.614

Review 5.  Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond.

Authors:  Walufu Ivan Egesa; Gloria Nakalema; William M Waibi; Munanura Turyasiima; Emmanuel Amuje; Gloria Kiconco; Simon Odoch; Patrick Kumbowi Kumbakulu; Said Abdirashid; Daniel Asiimwe
Journal:  Int J Pediatr       Date:  2022-10-08

Review 6.  Biomarkers and recent advances in the management and therapy of sickle cell disease.

Authors:  Marilyn J Telen
Journal:  F1000Res       Date:  2015-10-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.